RYE, New York, March 6, 2014 – Joan Fallon, founder and CEO of Curemark LLC, a research-driven biotechnology company focused on neurological disorders, will be a featured speaker at the SXSW Interactive Festival to be held March 7-11 in Austin, Texas.
SXSW Interactive, part of South by Southwest,™ brings together the brightest minds in cutting-edge technologies, digital creativity and startup innovation. Dr. Fallon will be joined by Amy Millman, President of Springboard Enterprises. They will discuss recommendations for tax and other incentives to help early-stage life sciences companies manage the formidable costs of research and development and intellectual property protection. The core conversation to take place at SXSW is an outgrowth of a 2013 White House briefing where Dr. Fallon initially presented her ideas.
As CEO of Curemark, Dr. Fallon leads her company’s effort toward developing CM-AT, the first novel treatment for autism. Curemark previously announced its successful Phase III clinical trial for CM-AT. There is currently no FDA-approved treatment for the core symptoms of autism.
“I am honored to be a speaker at this year’s SXSW Interactive and deeply grateful to be a part of such a cutting-edge forum,” Dr. Fallon said. “Start-ups are the lifeblood of American job creation and innovation. A package of incentives would provide significant help for small companies working on potential breakthroughs in life science technologies,” she added.
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark product CM-AT, its potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark product CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark product CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.